Is Coronavirus the Spark That Telehealth Needs?

Posted by Victoria Summers on Fri, Mar 13, 2020

Earlier this year, experts agreed that telehealth was poised to become mainstream in 2020. Spurred by broad access through smartphones and supported by health plans across the U.S., telehealth finally has the financial reimbursement and regulatory guidelines to enable patients and physicians to connect online. But now, COVID-19 has come on the scene. With the outbreak of the coronavirus in China and its rapid spread around the world, private companies and governments have encouraged people to quarantine themselves if they believe that they may have the virus. But how do patients know if they have it? If they suspect that they do have it, how can they access care in a way that doesn’t expose others? And if patients have health questions unrelated to coronavirus, wouldn’t they prefer to stay away from clinics and hospitals to decrease their risk of exposure?


>
Read More

Brand Positioning in Pharma: Where’s the Patient?

Posted by Jeanne Ryan on Mon, Sep 30, 2019

Patient centricity is a familiar buzzword in the pharmaceutical industry today. High medication costs and consumerism are leading patients to play a more influential role in their own treatment decisions. So when it comes to brand positioning, why do most pharma companies still largely target the prescribers?


>
Read More

Why You Need to Start Thinking About Meaningful Differentiation Much Earlier

Posted by Emily Mandell on Mon, Jul 01, 2019

Josh Hattem co-wrote this blog post with Emily Mandell.

“That's the problem with the American dream: It makes everyone concerned for the day they're gonna be rich.”

–President Bartlett, The West Wing

Pharma companies may have a winning asset, a winning development plan and an important disease target with unmet needs, but only one product can be first to market, only one can be the most efficacious and only one will become the standard of care. If your asset is entering a disease area with similar efficacy to an established standard of care, or if your asset is one of multiple products in a class entering within one to two years of one another, it’s critical to have a clear understanding of what it will take to meaningfully differentiate, and to do this early enough—in phase I or II—so there's enough time to correct the development plan.


>
Read More

Intelligent Process Automation: Starting Is Easy, Scaling Is a Different Ball Game

Posted by Vishal Kabra on Thu, May 09, 2019

Satish Jha co-wrote this blog post with Vishal Kabra 

Today, there is no denying that when it comes to increasing efficiency, reducing cost and offering a better customer experience, intelligent process automation (IPA) is a go-to strategy for businesses, and pharma is no exception. IPA promises that it can free up people to do more value-added work and play more strategic roles within their organizations. At a fundamental level, IPA is an emerging set of new technologies that include robotic process automation (RPA), conversational AI and machine learning to mimic activities carried out by humans. With the evolution in IPA technologies and the broad applicability of such automation, IPA continues to be a buzzword in every industry. Given the many benefits and possibilities, it’s understandable why organizations are jumping onto the IPA bandwagon.

However, most organizations aren’t succeeding at scaling intelligent process automation.


>
Read More

A New Delivery System for Next-Generation Cell and Gene Therapies

Posted by Maria Whitman on Thu, Apr 25, 2019

Kris Elverum of Turnstone Biologics co-wrote this blog post with Maria Whitman.

The evolution of medicines from small molecules to proteins has greatly advanced patient care, and up until now, our system of therapeutic delivery in the U.S. commercial system has been built with these therapeutics in mind. The next generation of cellular and gene therapies holds tremendous promise for patients, but only if the existing delivery system is revamped. There’s a real risk that most patients won’t benefit from these therapies as stakeholders struggle to find successful business models. In a recent article for Nature’s Gene Therapy, my industry colleague, Kris Elverum, and I take a critical look at the U.S. system and outline what needs to change to make approved cell and gene therapies accessible to patients.


>
Read More